Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users

Chen, Chih-Ken; Lin, Shih-Ku; Chen, Yi‐Chih; Huang, Ming-Chy; Chen, Tzu-Ting; Ree, Shao Chun; Wang, Liang‐Jen

doi:10.1016/j.drugalcdep.2014.12.035

Cited by 47 publications

(39 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al . [33] found that cognitive functioning in persistent MIP (duration of symptoms >1 month) was worse than that in other groups. They also classified the patients according to their psychotic symptoms and found out that like schizophrenia,[57] negative symptoms are strongly correlated with a poor cognitive performance in neuropsychological tests.…”

Section: Discussionmentioning

confidence: 99%

“…[262728293031] Not surprisingly, patients with MIP also have similar cognitive dysfunctions in working memory, episodic memory, information processing speed, and other EFs. [3233] Many developmental or accidental adverse events may affect EFs. [34] Executive dysfunctions are mainly related to neural dysfunctions in the frontal and parietal cortex, but many other cortical and subcortical pathways are likely to be involved in this pathology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study

et al. 2018

View full text Add to dashboard Cite

Background:Methamphetamine-induced psychotic disorder (MIP) cannot be easily differentiated from other psychotic disorders. Some studies have reported that patients with MIP and schizophrenia have differences in their cognitive functioning. We hypothesized that their performance would be different on neuropsychological tests which assess executive functions and visual memory.Materials and Methods:In a cross-sectional study, 30 patients with MIP, 31 patients with schizophrenia, and 31 healthy controls were assessed by Rey–Osterrieth complex figure (ROCF) test and visual search and attention test (VSAT). One-way analysis of variance was performed to compare the mean scores of tests. Tukey's HSD test was used for post hoc analysis.Results:Three groups had significant differences according to ROCF test (F = 15.76, P < 0.0001), VSAT (F = 39.78, P < 0.0001), left VSAT (F = 37.96, P < 0.0001), right VSAT (F = 40.40, P < 0.0001), and the time of the test administration (F = 3.26, P = 0.04). The post hoc analysis showed that the mean score of ROCF test and VSAT (total, right, and left) was significantly higher in the control group than in the other two groups. The time of administering the test in the control group was significantly shorter than in the MIP group (P < 0.03) and nonsignificantly shorter than in the schizophrenia group (P = 0.54). The mean score of right side VSAT was significantly higher in the MIP group than in the schizophrenia group.Conclusion:ROCF could not differentiate MIP from schizophrenia. The better performance of patients with MIP on right side VSAT that is reported in this and in the previous study needs to be reevaluated in more controlled studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Cognitive stability is also reduced among users of stimulants, indicated by the fact that intraindividual variability in cognitive performance is greater among users of methamphetamine compared with nonabusing controls, but the estimates only reached statistical significance among those who have experienced methamphetamine psychosis [13]. When individuals with different duration of methamphetamine-induced psychosis are compared, the cognitive impairment in those with persistent methamphetamine-induced psychosis resembles that seen in patients with schizophrenia, whereas those with transient psychosis are less impaired [14]. Also here, nonpsychotic patients with methamphetamine use showed less cognitive impairment.…”

Section: Cognitionmentioning

confidence: 92%

“…Two studies show similar cognitive impairment in those with psychosis induced either by amphetamines or by schizophrenia [14,15]. A study using inhibition tasks found great similarities in the ventrolateral prefrontal cortex, suggesting similarities in the underlying pathophysiology of psychosis induced by amphetamines and by schizophrenia [22].…”

Section: Complex Relationship Between Primary Psychosis and Amphetamimentioning

confidence: 99%

Psychosis induced by amphetamines

Bramness

Rognli

2016

Current Opinion in Psychiatry

View full text Add to dashboard Cite

During the past 18 months, studies have been published that cover risk factors, neuronal mechanisms, and treatment. These recent results do not differ from previous understandings, but the role of cognition and GABAergic dysfunction should be further investigated, and knowledge about resilience factors is still scarce. Also, a clearer evidence base for medical treatment of psychosis with concurrent amphetamine use is warranted. VIDEO ABSTRACT.

show abstract

“…The procedures of patient selection and assessment have been described elsewhere [26]. In brief, a cross-sectional, case-control design was proposed, with the following initial eligibility criteria for inclusion: (a) MA users with the experience of psychosis or patients with schizophrenia, both stable in symptoms under antipsychotic treatment; (b) age ≥18 years, and (c) of Han Chinese ethnic origin.…”

Section: Methodsmentioning

confidence: 99%

Differences in Clinical Features of Methamphetamine Users with Persistent Psychosis and Patients with Schizophrenia

Wang

Lin²,

Chen³

et al. 2016

Psychopathology

Self Cite

View full text Add to dashboard Cite

Background: Methamphetamine exerts neurotoxic effects and elicits psychotic symptoms. This study attempted to compare clinical differences between methamphetamine users with persistent psychosis (MAP) and patients with schizophrenia. In addition, we examined the discrimination validity by using symptom clusters to differentiate between MAP and schizophrenia. Methods: We enrolled 53 MAP patients and 53 patients with schizophrenia. The psychopathology of participants was assessed using the Chinese version of the Diagnostic Interview for Genetic Studies and the 18-item Brief Psychiatric Rating Scale. Logistic regression was used to examine the predicted probability scores of different symptom combinations on discriminating between MAP and schizophrenia. The receiver operating characteristic (ROC) analyses and area under the curve (AUC) were further applied to examine the discrimination validity of the predicted probability scores on differentiating between MAP and schizophrenia. Results: We found that MAP and schizophrenia demonstrated similar patterns of delusions. Compared to patients with schizophrenia, MAP experienced significantly higher proportions of visual hallucinations and of somatic or tactile hallucinations. However, MAP exhibited significantly lower severity in conceptual disorganization, mannerism/posturing, blunted affect, emotional withdrawal, and motor retardation compared to patients with schizophrenia. The ROC analysis showed that a predicted probability score combining the aforementioned 7 items of symptoms could significantly differentiate between MAP and schizophrenia (AUC = 0.77). Conclusion: Findings in the current study suggest that nuanced differences might exist in the clinical presentation of secondary psychosis (MAP) and primary psychosis (schizophrenia). Combining the symptoms as a whole may help with differential diagnosis for MAP and schizophrenia.

show abstract

Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users

Cited by 47 publications

References 32 publications

Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study

Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study

Psychosis induced by amphetamines

Differences in Clinical Features of Methamphetamine Users with Persistent Psychosis and Patients with Schizophrenia

Contact Info

Product

Resources

About